arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

PUMA BIOTECHNOLOGY, INC.

PBYI
$8.95 ▲ +0.81 (+9.95%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Good
Bullish
auto_awesome

Analytical Summary

PUMA BIOTECHNOLOGY, INC. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $447.6M
Dividend Yield
Revenue Growth -0.9%
Op. Margin 16.3%
ROIC 21.2%
FCF / Share $0.83
Trailing P/E 14.4x
Price / Book 3.5x
FCF Yield 9.3%
Debt / Equity 0.17
info Valuation on last close. End-of-day price, Aug 7, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$228.37M
↓ -0.9%
Net Income Profit after all expenses
$31.11M
↑ +2.8%
Operating Margin Operating profit as % of sales
16.3%
↑ +21.6% 69th
FCF / Share Free cash flow per share
$0.83
↑ +4.5%
Long-Term Debt Long-term obligations
$22.68M
↓ -66.7%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
74
Returns
90
Financial Health
76
Cash Quality
77

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 70 quarters